Author:
Clayton A J,Danson S,Jolly S,Ryder W D J,Burt P A,Stewart A L,Wilkinson P M,Welch R S,Magee B,Wilson G,Howell A,Wardley A M
Publisher
Springer Science and Business Media LLC
Reference26 articles.
1. Baculi RH, Suki S, Nisbett J, Leeds N, Groves M (2001) Meningeal carcinomatosis from breast carcinoma responsive to trastuzumab. J Clin Oncol 19: 3297–3298
2. Bendell JC, Domchek SM, Burnstein HJ, Harris L, Younger J, Kuter I, Bunnell C, Rue M, Gelman R, Winer E (2003) Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97: 2972–2977
3. Brufsky AM, Cleary D, Fuchs C, Lebish J, Baar J, Evans T, Lembersky B, Belani CP (2003) First-line chemotherapy for metastatic breast cancer (MBC) with docetaxel (T), carboplatin (C), and trastuzumab (H) (TCH): a phase II trial. Proc Am Soc Clin Oncol 22: A71
4. Clark GM, Sledge Jr GW, Osborne CK, McGuire WL (1987) Survival from first recurrence: relative importance of prognostic factors in 1015 breast cancer patients. J Clin Oncol 5: 55–61
5. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Frenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ (1999) Multinational study of the efficacy and safety of humanised anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17: 2639–2648
Cited by
332 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献